Location: Special Hospital Medico (Rijeka)
Study Drug: Experimental immunotherapy targeting the PD-L1 pathway, enhancing lymphocytes’ ability to destroy cancer cells more effectively.
Main Inclusion Criteria: Patients with locally advanced, inoperable, or metastatic squamous cell carcinoma of the skin who have not previously been treated with radiotherapy or systemic oncologic therapy. Patients who have undergone surgery in the past, and experienced a recurrence of the disease, may have received prior adjuvant treatment.
Status: Enrolling patients
Expected Start of Patient Enrollment: January 2024
Planned completion of new patient enrollment: August 2024
